Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger September 4, 2024 Read more >
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement July 22, 2024 Read more >
Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders November 9, 2023 Read more >
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders® August 28, 2023 Read more >
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting April 23, 2023 Read more >
Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson’s Disease and Movement Disorders® September 15, 2022 Read more >
Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting April 5, 2022 Read more >
Advances in Therapy publishes Pharma Two B’s review paper, “P2B001 (extended release pramipexole and rasagiline): A new treatment option in development for Parkinson’s disease” March 14, 2022 Read more >
Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease December 15, 2021 Read more >
Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea November 18, 2021 Read more >
Pharma Two B Announces Last Patient Out in Phase III Study of P2B001 in Early Parkinson’s Disease September 13, 2021 Read more >
Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors August 17, 2021 Read more >
Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive Officer January 6, 2021 Read more >
Pharma Two B Appoints David S. Tierney, M.D. as the Company’s Chief Executive Officer February 18, 2020 Read more >
First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson’s Disease February 6, 2018 Read more >
A Randomized Trial of a Low Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease April 3, 2017 Read more >
Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease June 30, 2015 Read more >
Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease June 30, 2015 Read more >
Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval April 22, 2011 Read more >
